LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Akcijų sąrašas・Compugen Ltd

Search

Compugen Ltd

Uždarymo kaina

1.95 -2.5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.95

Max

2.03

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-65M -7.7M
Pardavimai	-65M 2.2M
P/E Sektoriaus vid.	5.368 49.052
Pelnas, tenkantis vienai akcijai	-0.08
Pelno marža	-352.436
Darbuotojai	75
EBITDA	-64M -7.7M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+155.1% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-77M 193M
Ankstesnė atidarymo kaina	4.45
Ankstesnė uždarymo kaina	1.95

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-10 23:36; UTC

Uždarbis

Correction to Oracle Reports Higher 4Q Profit Article

2026-06-10 23:19; UTC

Karštos akcijos

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

2026-06-10 23:09; UTC

Pagrindinės rinkos jėgos

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

2026-06-10 23:04; UTC

Uždarbis

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

2026-06-10 20:44; UTC

Pagrindinės rinkos jėgos

Caterpillar Raises Quarterly Dividend 8%

2026-06-10 23:49; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Northern Star Should Take No Options Off The Table

2026-06-10 23:48; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

2026-06-10 23:48; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

2026-06-10 23:47; UTC

Rinkos pokalbiai

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

2026-06-10 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

2026-06-10 23:46; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

2026-06-10 23:38; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-10 23:38; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-10 23:38; UTC

Rinkos pokalbiai

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

2026-06-10 23:32; UTC

Rinkos pokalbiai

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

2026-06-10 23:20; UTC

Rinkos pokalbiai

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

2026-06-10 22:05; UTC

Rinkos pokalbiai

Correction to Bank of Canada Stays on Hold Market Talk

2026-06-10 21:57; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:52; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:35; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 21:22; UTC

Uždarbis

Oracle Stock Slides on Increased Capital Spending -- WSJ

2026-06-10 20:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-10 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-10 20:39; UTC

Rinkos pokalbiai

Uždarbis

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

2026-06-10 20:34; UTC

Uždarbis

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

2026-06-10 20:33; UTC

Uždarbis

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

2026-06-10 20:33; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-06-10 20:33; UTC

Rinkos pokalbiai

Uždarbis

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

155.1% į viršų

12 mėnesių prognozė

Vidutinis 5 USD 155.1%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Remiantis 3 analitikų, pateikusių Compugen Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Kitos sektoriaus akcijos

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat